Who
Joseph P. Lyssikatos
Chief Scientific Officer
Company insider
Files Form 4 as: Chief Scientific Officer, Enliven Therapeutics.
In numbers
- Trades disclosed
- 103
- Buys
- 0
- Sells
- 43
- Bought
- $0
- Sold
- $15.9M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 23 Feb 2023
- Last trade
- 12 Feb 2026
- Last filed
- 17 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 12 Feb 2026filed 17 Feb 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Code A | —18,750 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —112,500 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | ELVN Enliven Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —112,500 at $0.00 | filing |
| 12 Feb 2026filed 17 Feb 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Code A | —18,750 at $0.00 | filing |
| 6 Feb 2026filed 10 Feb 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $145K5,000 at $29.04 | filing |
| 6 Feb 2026filed 10 Feb 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $145K5,000 at $29.04 | filing |
| 20 Jan 2026filed 22 Jan 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $145K5,491 at $26.37 | filing |
| 20 Jan 2026filed 22 Jan 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $390K14,509 at $26.90 | filing |
| 20 Jan 2026filed 22 Jan 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $145K5,491 at $26.37 | filing |
| 20 Jan 2026filed 22 Jan 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $390K14,509 at $26.90 | filing |
| 9 Jan 2026filed 12 Jan 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.0M41,198 at $24.90 | filing |
| 9 Jan 2026filed 12 Jan 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.5M50,000 at $29.13 | filing |
| 9 Jan 2026filed 12 Jan 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.0M41,198 at $24.90 | filing |
| 9 Jan 2026filed 12 Jan 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.5M50,000 at $29.13 | filing |
| 8 Jan 2026filed 12 Jan 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $151K7,500 at $20.13 | filing |
| 8 Jan 2026filed 12 Jan 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $842K33,802 at $24.92 | filing |
| 8 Jan 2026filed 12 Jan 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $151K7,500 at $20.13 | filing |
| 8 Jan 2026filed 12 Jan 2026 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $842K33,802 at $24.92 | filing |
| 19 Dec 2025filed 23 Dec 2025 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $84K5,000 at $16.84 | filing |
| 19 Nov 2025filed 21 Nov 2025 | ELVN Enliven TherapeuticsBiotechnology | SEC FORM 4 Sold | $268K12,008 at $22.30 | filing |
News
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Expected to Rise, HC Wainwright Analyst SaysELVN · dailypolitical.com · 21 Oct 2026Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this YearELVN · prnewswire.com · 14 Oct 2026
0 headlines in the last 90 days name Joseph P. Lyssikatos; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.